You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBenzamidine
Accession NumberDB03127  (EXPT00669)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIKUE3ZY3J1F
CAS number618-39-3
WeightAverage: 121.1598
Monoisotopic: 121.076573298
Chemical FormulaC7H9N2
InChI KeyPXXJHWLDUBFPOL-UHFFFAOYSA-O
InChI
InChI=1S/C7H8N2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H3,8,9)/p+1
IUPAC Name
[amino(phenyl)methylidene]azanium
SMILES
NC(=[NH2+])C1=CC=CC=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Urokinase-type plasminogen activatorProteinunknownNot AvailableHumanP00749 details
Trypsin-1ProteinunknownNot AvailableHumanP07477 details
Casein kinase II subunit alphaProteinunknownNot AvailableHumanP68400 details
Kallikrein-6ProteinunknownNot AvailableHumanQ92876 details
Trypsin-2ProteinunknownNot AvailableHumanP07478 details
Trypsin-3ProteinunknownNot AvailableHumanP35030 details
Copper transport protein ATOX1ProteinunknownNot AvailableHumanO00244 details
Enoyl-CoA delta isomerase 1, mitochondrialProteinunknownNot AvailableHumanP42126 details
TrypsinProteinunknownNot AvailableStreptomyces griseusP00775 details
Suppressor of tumorigenicity 14 proteinProteinunknownNot AvailableHumanQ9Y5Y6 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Benzamidine.Approved, Investigational
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Benzamidine.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Benzamidine.Approved, Illicit, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Benzamidine.Experimental
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Benzamidine.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Benzamidine.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Benzamidine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Benzamidine.Approved
BoceprevirThe serum concentration of Benzamidine can be decreased when it is combined with Boceprevir.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Benzamidine.Approved, Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Benzamidine.Approved
CarbamazepineThe metabolism of Benzamidine can be increased when combined with Carbamazepine.Approved, Investigational
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Benzamidine.Withdrawn
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Benzamidine.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Benzamidine.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Benzamidine.Approved, Vet Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Benzamidine.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Benzamidine.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Benzamidine is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Benzamidine.Approved, Investigational, Vet Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Benzamidine.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Benzamidine.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Benzamidine.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Benzamidine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Benzamidine.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Benzamidine.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Benzamidine.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Benzamidine.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Benzamidine.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Benzamidine.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Benzamidine.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benzamidine.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Benzamidine.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Benzamidine.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Benzamidine.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Benzamidine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Benzamidine.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Benzamidine.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Benzamidine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Benzamidine.Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Benzamidine.Approved
GarlicThe serum concentration of Benzamidine can be decreased when it is combined with Garlic.Approved
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Benzamidine.Withdrawn
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Benzamidine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Benzamidine.Approved, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Benzamidine.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Benzamidine.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Benzamidine.Approved, Illicit
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Benzamidine.Approved
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Benzamidine.Approved, Withdrawn
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Benzamidine.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Benzamidine.Investigational
PethidineThe risk or severity of adverse effects can be increased when Benzamidine is combined with Pethidine.Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Benzamidine.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Benzamidine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Benzamidine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Benzamidine.Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Benzamidine.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Benzamidine.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Benzamidine.Approved
St. John's WortThe metabolism of Benzamidine can be increased when combined with St. John's Wort.Nutraceutical
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Benzamidine.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Benzamidine.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Benzamidine is combined with Temsirolimus.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Benzamidine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Benzamidine.Approved
TipranavirThe serum concentration of Benzamidine can be decreased when it is combined with Tipranavir.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Benzamidine.Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Benzamidine.Approved
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Benzamidine.Approved, Investigational
VerapamilThe metabolism of Verapamil can be decreased when combined with Benzamidine.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Benzamidine.Approved
Food InteractionsNot Available
References
Synthesis Reference

Takayuki Hara, Toru Minoshima, Masayasu Tabe, “Benzamidine derivatives and process for production thereof.” U.S. Patent US20050101675, issued May 12, 2005.

US20050101675
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5678
Blood Brain Barrier+0.8661
Caco-2 permeable-0.6125
P-glycoprotein substrateNon-substrate0.7427
P-glycoprotein inhibitor INon-inhibitor0.9915
P-glycoprotein inhibitor IINon-inhibitor0.9871
Renal organic cation transporterNon-inhibitor0.7423
CYP450 2C9 substrateNon-substrate0.7926
CYP450 2D6 substrateNon-substrate0.7624
CYP450 3A4 substrateNon-substrate0.8497
CYP450 1A2 substrateNon-inhibitor0.9705
CYP450 2C9 inhibitorNon-inhibitor0.958
CYP450 2D6 inhibitorNon-inhibitor0.9518
CYP450 2C19 inhibitorNon-inhibitor0.9862
CYP450 3A4 inhibitorNon-inhibitor0.9454
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9616
Ames testNon AMES toxic0.8675
CarcinogenicityNon-carcinogens0.7273
BiodegradationNot ready biodegradable0.6826
Rat acute toxicity2.5986 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9848
hERG inhibition (predictor II)Non-inhibitor0.9628
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility3.57 mg/mLALOGPS
logP-0.8ALOGPS
logP0.89ChemAxon
logS-1.6ALOGPS
pKa (Strongest Basic)11.53ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area51.61 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity48.53 m3·mol-1ChemAxon
Polarizability13.25 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassNot Available
Direct ParentBenzene and substituted derivatives
Alternative Parents
Substituents
  • Monocyclic benzene moiety
  • Carboximidamide
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organic cation
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
Gene Name:
PLAU
Uniprot ID:
P00749
Molecular Weight:
48507.09 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form against all of these substrates.
Gene Name:
PRSS1
Uniprot ID:
P07477
Molecular Weight:
26557.88 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein serine/threonine kinase activity
Specific Function:
Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coor...
Gene Name:
CSNK2A1
Uniprot ID:
P68400
Molecular Weight:
45143.25 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involv...
Gene Name:
KLK6
Uniprot ID:
Q92876
Molecular Weight:
26855.525 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
In the ileum, may be involved in defensin processing, including DEFA5.
Gene Name:
PRSS2
Uniprot ID:
P07478
Molecular Weight:
26487.55 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type peptidase activity
Specific Function:
Digestive protease specialized for the degradation of trypsin inhibitors. In the ileum, may be involved in defensin processing, including DEFA5.
Gene Name:
PRSS3
Uniprot ID:
P35030
Molecular Weight:
32528.565 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Metallochaperone activity
Specific Function:
Binds and deliver cytosolic copper to the copper ATPase proteins. May be important in cellular antioxidant defense.
Gene Name:
ATOX1
Uniprot ID:
O00244
Molecular Weight:
7401.575 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Intramolecular oxidoreductase activity
Specific Function:
Able to isomerize both 3-cis and 3-trans double bonds into the 2-trans form in a range of enoyl-CoA species.
Gene Name:
ECI1
Uniprot ID:
P42126
Molecular Weight:
32815.635 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Streptomyces griseus
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Not Available
Gene Name:
sprT
Uniprot ID:
P00775
Molecular Weight:
26776.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type peptidase activity
Specific Function:
Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site. Involved in the terminal differentiation of keratinocytes through prostasin (PRSS8) activation and filaggrin (FLG) processing.
Gene Name:
ST14
Uniprot ID:
Q9Y5Y6
Molecular Weight:
94769.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23